Biogen Inc. ( (BIIB) ) has released its Q2 earnings. Here is a breakdown of the information Biogen Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biogen Inc. is a leading biotechnology company focused on developing innovative therapies for neurological and rare diseases, leveraging its deep understanding of human biology to deliver transformative medicines.
In the second quarter of 2025, Biogen reported strong financial results, with total revenue reaching $2.6 billion, marking a 7% increase year-over-year. The company also raised its full-year guidance, reflecting a positive business outlook.
Key financial highlights include a GAAP diluted EPS of $4.33, up 8% from the previous year, and a Non-GAAP diluted EPS of $5.47, up 4%. The company saw significant growth in its Alzheimer’s, rare disease, and postpartum depression product lines, with notable sales increases for LEQEMBI and SKYCLARYS. Biogen also advanced its late-stage pipeline, with several Phase 3 studies initiated.
Looking forward, Biogen has increased its full-year 2025 guidance, expecting Non-GAAP diluted EPS to range between $15.50 and $16.00, and total revenue to remain approximately flat compared to 2024. The company remains focused on expanding its product portfolio and advancing its pipeline for sustainable growth.